The Role of Adjuvant Radiotherapy for Resected Non-Small Cell Lung Cancer in the Modern Era

The role of adjuvant therapy in resected non-small cell lung cancer has been a contentious issue for decades. The current standard of adjuvant chemotherapy1 was only proven by the completion of a series of modern international trials when a first set of older trials failed to demonstrate significant benefit.2 The Lung Adjuvant Cisplatin Evaluation meta-analysis of modern trials demonstrated a significant overall survival improvement of ∼5%.3 This does not seem to extend to molecular targeted therapies for resected Epidermal Growth Factor Receptor or ALK+ non-small cell lung cancer because improvement is seen only for progression-free survival, not for overall survival.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research